Comparative Pharmacology
Head-to-head clinical analysis: BRONKOMETER versus OXTRIPHYLLINE.
Head-to-head clinical analysis: BRONKOMETER versus OXTRIPHYLLINE.
BRONKOMETER vs OXTRIPHYLLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Clinical Note
moderateOxtriphylline + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Acemetacin
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Clotrimazole
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Clotrimazole can be decreased when combined with Oxtriphylline."